Feel Teal Twibbon 2016

IN USA SEPTEMBER IS NATIONAL AWARENESS MONTH

I cannot emphasise enough the importance of “awareness” when it comes to informing the public about ovarian cancer.
As an advocate/campaigner, I’ve spent the past 16 years attempting various methods of communicating this crucial information and have witnessed great movement during the years within the community, all proudly displaying their TEAL support.
Now for those of you who may be unfamiliar with the colour TEAL, please allow me to make things clearer.

Globally we know to “Think Pink” for Breast cancer and there’s a constant source of funding flowing as a result-
For Ovarian cancer to achieve the same status, “Feel Teal” came into existence.

It’s that simple.

But what can you do to help? That too is simple.
The Feel Teal Club invites you to add a Twibbon to your Twitter profile, showing your support for this cause.

http://twibbon.com/Support/feel-teal

When done, be sure to RETWEET and share share share!

From a whisper to a roar….ovarian cancer SILENT NO MORE!6b71d668bae4

Advertisements

Titan News

Whenever one of our Titan’s has information worth telling the rest of the world we are more than happy to share with our readers.
Sarah Weighknecht has recently become involved with a very exciting new company which not only offers great products and service but gives you the opportunity of joining their team!
IT WORKS shares an amazing Weight Loss programme designed to give you results using  their “system”. With 3 easy to follow steps you will be provided with the necessary resources and products to assist in achieving the goals you seek. Download the SYSTEM

But its not just about weight loss as IT WORKS also have a range of Skin, Hair and Nail care products along with Organic greens and Supplements to assist your dietary needs and requirements.
Each product is completely “natural”, a bonus plus for everyone!

IT WORKS is a Global business offering service and deliveries just about anywhere.

As a new Distributor for IT WORKS, Sarah is inviting our readers to check out her website for further information about each product and is more than happy to answer and of  your questions. wrapswithsarahwf.myitworks.com
This could be the business opportunity you were looking for to earn those extra $$$!

IT WORKS 2IT WORKS 4IT WORKS 3

 

Age and ovarian cancer

female_symbol_color_colour_dark_turquoiseOvarian cancer is cancer of the ovaries. Women are born with two ovaries, one on each side of the uterus. A woman’s ovaries are small, about the size of an almond. Though small, they’re responsible for many reproductive functions.

Ovarian cancer can be very difficult to detect and diagnose. Many of the symptoms of ovarian cancer are similar to symptoms caused by much less serious problems, including indigestion and bloating. Because the ovaries are deep within the pelvis, there often are neither signs nor symptoms of early ovarian cancer. Some cases of ovarian cancer will not be diagnosed until the cancer has spread to a woman’s abdomen or elsewhere within the pelvis. Unfortunately, ovarian cancer that has progressed this far is very difficult to treat. While the cancer remains confined to the ovaries, doctors have an easier chance of treating it. Advanced stages of ovarian cancer are frequently fatal.

Ovarian cancer occurs most frequently in older women. Ovarian cancer rates are highest in women aged 55-64 years.
The median age at which women are diagnosed is 63, meaning that half of women are younger than 63 when diagnosed with ovarian cancer and half are older. Ovarian cancer is rare in women younger than 40. However, it’s also possible for younger women and even adolescent girls to be diagnosed with a type of ovarian cancer.
According to research many cases in younger women have germ cell tumors, which is a different type of tumor from [the more common] epithelial tumor.

ftc-tealgirl.

For further reading please view these links:
http://www.ovariancancer.org/about/statistics/

http://www.macmillan.org.uk/Cancerinformation/teensandyoungadults/Cancertypes/Ovariancancer/Signsandsymptoms.aspx


All women are at risk of ovarian cancer
Awareness of the early warning signs of the disease could save lives
Diagnosis at an early stage vastly improves a woman’s chance of survival
Ovarian cancer is often diagnosed at a late stage.
Many women mistakenly believe the cervical smear test (Pap test) will detect ovarian cancer

measure of benefit-ovarian cancer

Ovarian Cancer: New Measure of Benefit Proposed

Veronica Hackethal, MD
January 07, 2015

For patients with ovarian cancer who are in remission, the probability of remaining disease-free improves considerably over time, and conditional disease-free survival might be a good estimate of prognosis for these patients, according to a new study.
The study, which was published in the December issue of Journal of Clinical Oncology, is the first to look at conditional disease-free survival in patients with ovarian cancer.
“We observed that at time of remission, the probability of staying disease-free for 3 more years was 48%. This increased to 98% for patients who had remained disease-free for 5 years after remission,” said lead author Brenda Diergaarde, PhD, assistant professor of epidemiology at the University of Pittsburgh Cancer Institute.
Prognosis usually improves over time, Dr Diergaarde pointed out. Traditional survival estimates, like overall survival (estimated at diagnosis) and disease-free survival (estimated at remission), might not apply to patients in remission for a certain period of time.
Conditional disease-free survival, however, takes into account changes in the probability of remaining disease-free over time, as well as the amount of time since achieving remission, Dr Diergaarde explained.
“Time elapsed since remission should be taken into account when making follow-up care decisions,” Dr Diergaarde emphasized. “Having more accurate information about the risk of recurrence will allow patients and clinicians to make better informed decisions regarding follow-up care after ovarian cancer treatment. It may also lead to a better quality of life [for patients] because a more accurate prognosis can ease their fears about the cancer coming back.”
Estimation of Conditional Disease-free Survival
In their study, Dr Diergaarde and colleagues used data from 404 patients with ovarian, fallopian, and peritoneum cancer who were diagnosed from 2003 to 2008 and who had achieved remission. All patients were part of the large case–control Hormones and Ovarian Cancer Prediction (HOPE) study.
The HOPE study involves patients from western Pennsylvania, eastern Ohio, and western New York who entered the study within 9 months of their diagnosis. Researchers gathered demographic and lifestyle information at study enrollmentImage1, and used medical records to obtain information on disease, treatment, and outcomes. They calculated disease-free survival as the amount of time between remission and recurrence, or date of last contact, and estimated conditional disease-free survival from cumulative disease-free survival estimates.
Most patients (96.8%) were white, and 5.5% had a family history of ovarian or breast cancer. Patients who had already survived 1, 2, 3, 4, or 5 years had a probability of 3 more years of recurrence-free survival of 63.8%, 80.5%, 90.4%, 97.0%, and 97.7%, respectively.
The probability of being disease-free 5 years after achieving remission increased from 44.6% at baseline to 63.3%, 80.5%, 92.4%, and 99.2%, respectively, 1, 2, 3, and 4 years into remission.
Although conditional disease-free survival always increases as the number of years spent in remission increases, certain subgroups in this study experienced larger increases, Alexia Lasonos, PhD, a biostatistician at the Memorial Sloan Kettering Cancer Center in New York City, pointed out in an accompanying podcast.
“The increase was larger for patients above 65 years of age, patients with advanced-stage disease, serous histology, and poorly differentiated tumors,” Dr Lasonos said. “This indicates that conditional disease-free survival improves most for patients who initially had the poorest prognosis.”
At the time of remission, disease-free survival estimates also varied, depending on age, stage, histology, and grade. These factors were important for patients who remained in remission for 3 years, she explained.
“If a patient was still in remission 4 years later, her age, stage, histology, and grade at diagnosis were no longer diagnostic in terms of disease-free survival,” she added. “What mattered most at that time is the fact that the patient had been in remission for 4 years.”
Dr Lasonos urged caution, though, when interpreting the results of this study. Conditional disease-free survival estimates always have a larger degree of uncertainty than baseline estimates, she noted. This is because fewer patients remain in remission over time.
In addition, results suggest that risk for recurrence is significantly higher in patients on maintenance chemotherapy. However, high-risk patients are more likely to have received maintenance chemotherapy, which could have biased these results. Other limitations of the study could have been its observational nature and its lack of a standardized surveillance group.
Nevertheless, Dr Lasonos commended Dr Diergaarde’s team for their work.
“With new successful treatments and advances in immunotherapy that have extended time in remission for this patient population, these conditional estimates become more relevant for ovarian cancer patients,” Dr Lasonos emphasized.
Future research will need to focus on developing prognostic tools that take time in remission into account, she concluded.
‘Important Contribution’
“This is an important contribution to both the literature and the discussion of the way survival outcomes might optimally be presented to cancer patients,” said Maurie Markman, MD, senior vice president for clinical affairs at the Cancer Treatment Centers of America in Philadelphia, and Medscape video blogger for Markman on Oncology, who was not involved in the study.8796875_f520
“Until this report, we really did not have a solid strategy to develop specific numbers that could be provided to patients who have already survived a period of time without recurrence,” Dr Markman explained. “Hopefully, in the future, the concept of conditional disease-free survival will become a regular part of discussions within the oncology community and with patients,” he said.
Dr Diergaarde and Dr Lasonos have disclosed no relevant financial relationships. Dr Markman reports receiving fees from Celgene, Caris Life Sciences, Novartis, sanofi-aventis, Amgen, and Genentech.
Article courtesy www.medscape.com/

Quality diet and ovarian cancer

Women with an overall higher quality diet prior to diagnosis with ovarian cancer may have a lower risk of all-cause mortality, according to data taken from the Women’s Health Initiative.

Those women with a small waist circumference and without a history of diabetes may have an even greater protective effect, the study found.

“In this analysis, none of the individual dietary components was associated with mortality after ovarian cancer, suggesting that it is the overall dietary pattern that is relevant,” wrote researchers led by Cynthia A. Thomson, PhD, RD, of Canyon Ranch Center for Prevention and Health Promotion at the University of Arizona. “A large, randomized, controlled trial is currently underway to test the hypothesis that dietary changes toward higher Healthy Eating Index, along with physical activity, adopted after treatment for stage II-IV ovarian cancer will improve progression-free survival.”

The study, published in the Journal of the National Cancer Institute, looked at 636 women with ovarian cancer from the Women’s Health Initiative Observational Study of Clinical Trials, which included postmenopausal women followed from 1995 to 2012. The researchers measured dietary quality using the Healthy Eating Index, a food frequency questionnaire. The questionnaire assessed dietary factors including intake of whole fruits and vegetables, dark green and orange vegetables, whole grains, milk, meat, beans, and fats. The women were separated into three groups based on dietary quality.

The researchers found that women with the highest-quality diet had a 27% decreased all-cause mortality after ovarian cancer diagnosis compared with women in the lowest tertile for dietary quality (HR = 0.73; 95% CI, 0.55-0.97). Specifically, a 40% lower mortality risk was found in those women with a waist circumference of 88 cm or less. A 27% lower risk was found in those women with no prior history of diabetes.

When patients were stratified according to physical activity levels, the researchers observed no modification of the association between diet quality and survival.

“Whether changing diet to increase diet quality score after ovarian cancer diagnosis would offer improvement in mortality is yet to be determined,” the researchers concluded.
Article courtesy: http://www.cancernetwork.com/diet-quality-ovarian-cancer-diagnosis-linked-survival

VegFruits

 

Hysterectomies and Morcellators

What is a Power Morcellator? A device used in hysterectomies to cut tissue into small pieces to be removed from the body. However, uterine cancers sometimes go undetected prior to the procedure. In these cases, the morcellator dices up and spreads unsuspected cancer inside the woman’s body.

Hysterectomy is the 2nd most common surgery among women in the United States

By age 70, one out of three American women will have had a hysterectomy

90% of these surgeries are done to remove Fibroids (non-cancerous tumors found in the uterus)

The average life span following accidental morcellation of sarcoma is only 24-36 months

Only 15% of women who have leiomyosarcoma (LMS) that has spread (stage 4) will be alive after 5 years

Women with sarcoma who are morcellated are about 4 times more likely to die from sarcoma than if they had not been morcellated.

http://www.recallcenter.com/power-morcellator/lawsuit/

Further reading: http://www.fda.gov/medicaldevices/safety/alertsandnotices/ucm393576.htmP1-BP784_CANCER_G_20140411230202

Breakthrough for ovarian cancer

Ovarian Cancer Breakthrough
The first treatment for advanced ovarian cancer in more than a decade has just been made more widely available to Australian patients.

It will be subsidised for women with stage 3 and 4 ovarian cancer in cases where surgery isn’t sufficient treatment.

Clinicians and patients say it’s a huge breakthrough for women who have so far had limited options.cooltext1606276668

 

For text discussion: http://www.abc.net.au/worldtoday/content/2014/s4063447.htm